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Abstract: Spray drying as a particle engineering technique is of increasing interest in the field of
inhalation and is already being utilised e.g., for the PulmoSphereTM products. As spray dried
particles tend to agglomerate and are mechanically instable, low dose filling processes can be
difficult. This study correlates powder flowability tests of spray dried formulations with filling
processes with drum and dosator systems. Four pulmonary and four nasal powders with different
characteristics in terms of shape, composition, and surface polarity were prepared and characterised
for powder flowability according to Ph. Eur. and by powder rheometry. All formulations were
filled with a manual drum TT and a dosator system. The classical flowability tests according to the
Ph. Eur. showed a bad flow behaviour for hydrophilic pulmonary powders (x50 ~ 3 µm), whereas
hydrophobic pulmonary particles and nasal particles (x50 ~ 25 µm) showed a better flowing behaviour.
Powder rheometry supports this finding but can better differentiate flow behaviours.
Keywords: pulmonary application; nasal application; filling process; vacuum drum; dosator;
FT4 powder rheometer; flowability tests
1. Introduction
In drug delivery to the respiratory tract, the fundamental issue is to deposit the drug particles in
the targeted tissues. For pulmonary application of dry powders, a very small particle size of below
five micrometres in aerodynamic diameter is necessary [1]. For nasal application, however, a particle
size > 10 µm is regarded as suitable in order to avoid a major share of particles being inhaled to the
lungs [2]. Spray drying as a bottom up technology offers the possibility to develop formulations in the
needed size range. Being a particle engineering technique, specific needs can be addressed and the
particles can be designed accordingly and the formulation of sensitive APIs like proteins or peptides is
possible as well [3]. Inhalable insulin, for example, was formulated as a dry powder by spray drying
and distributed as Exubera® [4,5]. It was a stabilised amorphous formulation and was advantageous
to the aqueous solution in terms of storage stability, applicable mass, and low microbial growth [4].
Likewise, an enzyme formulation of superoxide dismutase, an antioxidant enzyme, which can be
used in treatment of cancer, arthritis, and respiratory distress syndrome could be developed with
spray drying [6]. For this purpose, the superoxide dismutase was induced into a liposome carrier
and spray dried with disaccharide stabilisers, which resulted in an unaffected enzyme activity [6].
Furthermore, the possibility to create formulations for local high-dose and systemic delivery are
promising aspects. For pulmonary high-dose delivery, e.g., needed for antibiotic therapy, spray drying
may also be a versatile formulation technology. In the course of that, the PulmoSphereTM technique is
already being utilized, and products are available on the market [7,8]. Spray dried powders further
allow for embed nanoparticles, creating nano-in-microparticle composites. This strategy can be used
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to administer drug nanocrystals of poorly water soluble drugs or polymeric nanoparticles, e.g., being
loaded with antigen for mucosal vaccination, to the nose and the lung, respectively [9].
Unlike in standard formulations for inhalation, mostly comprising a large carrier which dominates
the bulk powder properties such as density and mechanical stability, spray dried products consist
of small particles only. Thus, the bulk material properties are governed by the spray dried product
properties (small size, low density). Due to the overall small particle size of spray dried formulations for
respiratory administration, the handling and processing of these powders are afflicted with difficulties.
The large surface area leads to uncontrolled agglomeration and may hamper the filling process [10].
Further, spray dried materials are oftentimes less dense and of low mechanical stability, thus, the filling
process itself can have a negative impact on the success of inhalation, as the powder gets compacted and
may not be re-dispersed very well [11]. To avoid issues accounting for high cohesion, surface-active
excipients such as L-leucine can be added before spray drying [12]. Alternatively, the particle
morphology can be designed to reduce the contact area of the particles [3,13]. This approach is
oftentimes realised with hollow spheres, sometimes corrugated, where low mechanical stability can be
an issue during the filling process as the particles might be destroyed by mechanical stress. To gain
insight in important powder properties critical to the filling process, previous studies evaluated coarse
powders or interactive blends [14,15]. It was found that the bulk density, basic flowability energy,
and wall friction angle had an influence on the fill weight of inhalation carriers. Fines as a more cohesive
group of powders were also evaluated and found to be challenging to fill with the dosator system.
This study represents an approach to characterise spray dried formulations of particle sizes needed for
inhalation by means of classical flowability tests and powder rheology. Furthermore, the impact of
filling-induced powder changes on aerodynamic behaviour is exemplarily for some formulations.
2. Materials and Methods
2.1. Preparation of Model Formulations
Pulmonary particles of an intended particle size < 5µm were prepared by spray drying a 2% (w/w%)
solution of mannitol (Roquette, Lestrem, France), erioglaucine disodium (0.5% calculated on the solid
mass; Sigma-Aldrich, Saint Louis, MO, USA) and different excipients to adjust the morphology (Table 1).
Erioglaucine disodium, also known as brilliant blue (BB), was used as a model “drug” substance
in this study. Hydrophilic spherical particles (P/S/phil) were obtained by spray drying the solution
using a Büchi Mini Spray Dryer B-290 (Büchi Labortechnik AG, Flawil, Switzerland) equipped with a
high-performance cyclone and a two-fluid nozzle of 1.5 mm inner diameter. The inlet temperature was
set to 130 ◦C, and the outlet temperature was adjusted with the liquid feed pump rate to 64 ◦C. The Mini
Spray Dryer was operated at an aspirator flow rate of 100% (35 m3/h) and an atomising air volume of
470 m3/h. To induce a wrinkled morphology in hydrophilic particles (P/W/phil), 0.02% (1% calculated
on the solid mass) hydroxypropylmethylcellulose (HPMC 4000, Shin-Etsu, Wiesbaden, Germany) was
added to the solution. For hydrophobic spherical particles (P/S/phob) leucine (Sigma-Aldrich) was
added in a moderate concentration of 0.2% to the solution. Hydrophobic wrinkled particles (P/W/phob)
were prepared by increasing the leucine concentration to 30% calculated on the solid mass. The spray
drying conditions were the same for all pulmonary formulations.
Larger nasal particles (targeted particle size was 20 µm–30 µm) were likewise prepared in four
different varieties. Hydrophilic spherical particles also consisted of mannitol and BB but were spray
dried from a 10% (w/w%) solution. The BB content was 0.1% (N/S/phil) calculated on the solid mass.
Wrinkled hydrophilic particles (N/W/phil) had 1% HPMC 4000 added to them. Hydrophobic spherical
particles (N/S/phob) had 10% leucine calculated on the solid mass added and the wrinkled (N/W/phob)
18% leucine. The solutions were spray dried with the Büchi Mini Spray Dryer B-290 and a 60 kHz
ultrasonic nozzle set to 1.6 Watt to create larger droplets and a lower aspirator rate of 50% to increase
the drying time. An inlet temperature of 130 ◦C was set and the outlet temperature was adjusted with
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the pump rate to 60 ◦C. All powders were stored in a dry desiccator to avoid uptake of humidity after
preparation and to allow after drying.
Table 1. Overview of composition of developed formulations for pulmonary and nasal application.
P/S/phil P/W/phil P/S/phob P/W/phob N/S/phil N/W/phil N/S/phob N/W/phob
Solid content in spray dried
solution (w/w) 2% 2% 2% 2% 10% 10% 10% 10%
Concentration brilliant blue
(w/w) in particles 0.5% 0.5% 0.5% 0.5% 0.1% 0.1% 0.1% 0.1%
Concentration mannitol
(w/w) in particles 99.5% 98.5% 89.5% 69.5% 99.9% 98.9% 89.9% 81.9%
Concentration of added
excipient (w/w) in particles -
HPMC
4000 1%
Leucine
10%
Leucine
30% -
HPMC
4000 1%
Leucine
10%
Leucine
18%
2.2. Bulk Characterisation
2.2.1. Morphology
Morphology was evaluated by scanning electron microscopy (SEM; Phenom XL, Phenom-world;
Eindhoven, the Netherlands). The samples were prepared by fixing the particles onto a carbon sticker
and sputter-coated with a 20 nm gold layer. A backscattering detector and a working voltage of 10 kV
were used.
2.2.2. Particle Size Distribution (PSD)
The PSD was assessed with a HELOS laser diffractometer (Sympatec GmbH, Clausthal-Zellerfeld,
Germany) with the RODOS dispersing system. Pulmonary particles were dispersed at 3 bar and
nasal particles at 0.2 bar to ensure particle integrity. Data analysis was performed by the Windox
5.8.0.0 software from Sympatec (Clausthal-Zellerfeld, Germany) utilising the Fraunhofer theory.
The reported data is the mean value of three-fold determination. The span value was calculated with
the following Equation (1):
Span = (x90 − x10)/x50 (1)
2.2.3. Contact Angle (CA)
The contact angle (CA) was determined on a pressed specimen (achieved with a hydraulic press
PW 10 from Paul-Otto Weber GmbH, Remshalden, Germany) of the produced material with a mixture
of water/glycerol (70:30), as pure water could not be measured due to high capillarity of the hydrophilic
formulations. The liquid was dropped on the surface of the pressed specimen and the mean angle of
contact between the surface and the droplet (measured with a goniometer Type G1 from Krüss GmbH,
Germany) is reported as the mean of six measurements.
2.2.4. Specific Surface Area (SSA)
Utilising the Brunauer-Emmett-Teller-equation the specific surface area was determined with
a Gemini 2360 (Micromeritics, Norcross, GA, USA) and nitrogen as testing gas. Mean values were
calculated of three measurements of the multiple point BET and reported with the standard deviation.
2.2.5. Bulk and Tapped Density
The bulk density (BD) was assessed by determining three times the volume of 25 g (Sartorius BP
3100 S, Göttingen, Germany) formulation in a 100 mL measuring cylinder with an accuracy of 1 mL.
The cylinder was tapped 10, 500, 750, and 1250 times on an Erweka SVM (Erweka, Langen, Germany)
to obtain the tapped density (TD). If the volume did not change more than 1 mL in between the 750 and
1250 taps, the volume of 1250 taps was reported as the tapped volume (according to the Ph.Eur. 9.4
(2.9.34)). If the change was more than 1 mL, the sample was tapped repeatedly in 1250 steps until the
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specification was met. The ratio of the mass and tapped volume was calculated as the tapped density.
To determine compressibility the Hausner ratio (HR) and compressibility index (CI) were calculated
and evaluated according to the Ph. Eur.
2.2.6. Flow Through an Orifice (FtO) and Angle of Repose (AoR)
The flow through an orifice was determined by placing a metal hopper containing 20 g of
formulation on a conical orifice with a diameter of 25 mm in a granulate flow tester (GTB Granulate
Flow Tester, Erweka). A vessel to collect the outflowing powder was set on a balance and the time was
measured for the powder to pass through the orifice. For very poor flowing powders, it was possible
to stir the powder. The data was reported as the mean of three measurements in s/100 g.
The angle of repose was tested with the granulate flow tester (Erweka) equipped with a 25 mm
orifice in case of very cohesive powders (P/S/phil and P/W/phil) and 15 mm orifice for better flowing
powders. In a hopper above the nozzle, the formulation was stored and flowed onto a base with a
fixed diameter. The determination of the repose angle was done with the assistance of a laser and
repeated three times, so the mean value could be calculated.
2.3. FT4 Measurements
2.3.1. Powder Stability Measurements
Powder stability was assessed using an FT4 Powder Rheometer (Freeman Technology,
Worcestershire, UK). Seven identical test cycles with a blade running at a speed of 100 mm/s downward
through the sample were conducted and the energy was measured, which was needed to stir the
powder. The ratio of the energy of test 7 and test 1 was deduced as the stability index (SI). An index of
0.9–1.1 indicates a robust material, which is not affected by stirring [16]. The measured energy of test
7 was taken as the basic flow energy (BFE), which is needed to overcome the resistance of the powder to
flow [17]. To test the sensitivity of the powder, a test sequence with different blade speeds followed the
stability test. The speed was reduced to 70, 40 and 10 mm/s, the Flow Rate Index (FRI) was calculated
as the ratio from the energy of the last test and the energy needed for the 100 mm/s in the beginning.
An FRI ~ 1 indicates that a powder is insensitive to change in flow rate. Most powders exhibit an
average flow rate sensitivity of 1.5 < FRI < 3.0 and very cohesive powders a high sensitivity with an
FRI > 3.0 [18]. During the upward movement of the blade, the specific energy (SE) was recorded as a
measure of powder flow in a low stress environment. At an SE < 5, the powder is of low cohesion,
between 5 and 10 of moderate cohesion, and an SE > 10 results for highly cohesive powders [17–19].
2.3.2. Powder Compressibility
Compressibility measurements were carried out with a vented piston. A vertical stress in steps
of 0.5–15 kPa was applied and the change in powder bed height due to the powder compaction was
measured. The compressibility was calculated as a percentage change in volume [20] and classified
according to the Carr’s index (CI, Ph. Eur. 9.4). Cohesive powders have a high compressibility due to
agglomeration and large amounts of air entrapped in the bulk.
2.3.3. Shear Cell Measurements
Shear cell tests were conducted with the 1 mL shear cell to achieve an understanding of the flow
behaviour of a consolidated powder. The measurement starts with a conditioning step to ensure the
same packaging in every sample. Afterward, a pre-compression with a vented piston is applied to
obtain reproducible results with well-defined failure points [21]. This is followed by diving of the shear
head into the powder bed generating a vertical stress. If the required stress is established, the shear
head starts to rotate and induces the shear stress. The maximum shear stress, just before the powder
bed fails, is recorded as the yield point. Plotting the yield points against their corresponding normal
stress allows determination of the major principle stress and the unconfined yield strength. The ratio of
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the major principle stress and the unconfined yield strength is reported as the flow function coefficient
(ffc) [21,22]. An ffc < 4 indicates a cohesive powder, an ffc of 4–10 an easy flowing powder and > 10 a
free flowing powder according to Jenike’s classification [22,23].
2.4. Filling Trials
2.4.1. Drum TT
The Drum TT (Harro Höfliger, Allmersbach im Tal, Germany) is a manually operated lab table
unit for dosing trials, which can be equipped with a drum with different dosing bores (Figure 1).
In this study, dosing bores with a volume of 15 mm3 for pulmonary formulations and 30 mm3 for
nasal formulations were used, which were filled by the applied vacuum. As a maximal vacuum of
−0.6 bars could be selected and −0.4 bars were set as moderate filling condition. To support the filling
process, a stirrer implemented in the hopper above the dosing bore was turned manually three times.
The ejected plugs were weighed (Sartorius analytical balance), and the mean value of 20 doses and
the relative standard deviation (RSD) were calculated. A filling trial was considered uniform at an
RSD < 10%.
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2.4.2. Dosator
To simulate the filling process with another filling system, a dosator table test station was utilised
(Figure 2). A solitary pin suitable to fill capsules size 3 was implemented. To obtain a homogeneous
powder bed with a smooth surface excessive powder was removed from the reservoir in every direction
before a dose was taken with the pin, resulting in a 3 mm powder bed height. The powder had been
sieved beforehand to destroy large agglomerates hampering the powder bed preparation. The pin
separated one dose at a time from the bulk and compacted it to 1 mm height. In this manner, 20 doses
were taken, and the mean plug weight and RSD were evaluated.
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2.4.3. Aerodyna ic Perfor ance of Dosed Powder Plugs
For aerodyna ic characterisation, the e itted dose and fine particle fraction for chosen
for ulations were determined. The test of emitted dose (ED) was derived from the Ph. Eur.
9.4. A flow rate assuring a 4 kPa pressure drop over the device was set, that was 55.0 L/min for the
Twister® device (Aptar Pharma, Le Vaudreuil, France). Five individual doses were emitted from
the Twister® device without the device being cleaned in between the shots. The emitted dose was
collected in the dose uniformity sampling apparatus, and the amount of brilliant blue, being present in
all particles, was quantified via UV/Vis-spectroscopy at a wavelength of 630 nm.
The fine particle fraction (FPF) as assessed according to the Ph. Eur. 9.0 (2.9.18) ith a next
generation impactor (NGI) at a flow rate as described previously. To retain the powder in the collection
cups the cup surface was coated with a mixture of Brij 35, ethanol, and glycerol (15/51/34%, w/w).
A filter was set after the multi orifice collector (MOC). Quantification was conducted as stated above
and data evaluation was performed with the Copley Inhaler Testing Data Analysis Software (Copley
Scientific, Nottingham, UK). The percentage of particles of the emitted dose below five micrometres is
determined as fine particle fraction (FPF).
3. Results and Discussion
As the pulmonary and nasal formulations differ in particle size, even though all are micronised
powders, an improved flowability was anticipated for the nasal formulations due to their larger
particle size. This should be reflected in the classical flowability test according to the Ph. Eur. and the
FT4 measurements. Further, it was expected, that indented particles would show a worse flow and
filling behaviour, because the indentations could interlock. A hydrophobic surface could improve flow
and filling characteristics due to weaker particle-particle interactions. For powder filling, especially for
low doses as common in respiratory delivery, powder flow and powder compressibility are important
parameters determining the success of powder filling. Thus, spray dried powders for respiratory
delivery will be especially challenging to fill. Further, the filling process is anticipated to have an
influence on the ED and FPF, as the built-up plugs may not be well dispersed, and large agglomerates
could remain in the device.
3.1. Characterisation of Bulk Properties
Spray drying resulted in particles in their respective targeted size range (Table 2).
Pulmonary formulations had a particle size < 5 µm with a comparable size distribution, whereas the
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nasal formulations were >10 µm [2] due to a higher concentration of solution used and the use of an
ultrasonic nozzle.
Table 2. Characterisation of pulmonary formulations (left) and nasal formulations (right). All values
(except CA) are the mean of a threefold determination ± standard deviation. The CA values are the
mean of a six-fold measurement ± standard deviation.
Parameter P/S/phil P/W/phil P/S/phob P/W/phob N/S/phil N/W/phil N/S/phob N/W/phob
PSD in µm 2.73 ± 0.02 2.92 ± 0.02 2.74 ± 0.03 2.66 ± 0.06 23 ± 0 26 ± 1 23 ± 0 27 ± 1
Span 1.86 1.86 1.91 2.08 1.01 1.93 2.44 1.69
CA in ◦ 26 ± 4 33 ± 3 67 ± 9 85 ± 3 28 ± 4 25 ± 2 69 ± 4 81 ± 5
SSA in m2/g 1.88 ± 0.02 2.18 ± 0.04 1.55 ± 0.11 3.28 ± 0.07 0.38 ± 0.03 0.86 ± 0.04 0.96 ± 0.08 0.95 ± 0.04
BD in g/mL 0.23 ± 0.00 0.27 ± 0.00 0.36 ± 0.00 0.26 ± 0.00 0.36 ± 0.01 0.49 ± 0.01 0.47 ± 0.01 0.24 ± 0.00
TD in g/mL 0.33 ± 0.01 0.39 ± 0.00 0.56 ± 0.00 0.44 ± 0.02 0.48 ± 0.01 0.60 ± 0.00 0.66 ± 0.00 0.37 ± 0.01
HR 1.45 ± 0.02 1.43 ± 0.02 1.54 ± 0.01 1.70 ± 0.07 1.32 ± 0.03 1.23 ± 0.01 1.39 ± 0.03 1.56 ± 0.05
CI in % 31 ± 1 30 ± 1 35 ± 1 41 ± 2 24 ± 2 18 ± 0 28 ± 1 36 ± 2
Classification of flow
according to Ph. Eur. Poor Poor Very poor
Extremely
poor
Slightly
poor Fair Poor Very poor
AoR in ◦ 37 ± 3 46 ± 1 41 ± 2 40 ± 2 36 ± 1 31 ± 3 20 ± 3 34 ± 3
Fto in s/100 g 37 ± 5 148 ± 45 1 ± 1 2 ± 0 4 ± 3 1 ± 0 1 ± 0 2 ± 0
Leucine is known to form a shell in the early drying stage which leads to a hydrophobic surface
and can alter the shape of the particles [12]. Measurements of the contact angle (Table 2) are in
agreement with this. All powders can be moistened as the measured CA is below 90◦. The addition of
HPMC as hydrophilic excipient did not have an influence on the CA. Leucine as a hydrophobic amino
acid with an aliphatic sidechain, in contrast, is poorly soluble in water. With this hydrophobic element
being added to the powder, the CA increased to 85◦. As the CA increased further the more leucine was
added, this seems to be concentration-dependent. A change in morphology from spherical to indented
(Figure 3) was induced as well by leucine. Particles consisting of mannitol and brilliant blue exhibited
a spherical morphology. Adding 10% leucine did not alter the spherical appearance but the surface
was slightly more uneven than for the particles not containing leucine. Increasing the leucine amount,
the particles collapsed and became corrugated. HPMC had the same effect as leucine with respect to
indentations, but its appearance was different. The area around large indentations was more structured
with smaller wrinkles than those of the indented particles with leucine. Consequently, the surface area
increased for the wrinkled particles compared to the spherical ones. Likewise, a decreased bulk density
was to be expected. This could be observed for the hydrophobic particles, whereas the hydrophilic
particles showed a higher tendency to agglomerate; thus, the effect of the morphology on the density
was cancelled out.
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Whereas the bulk and tapped density is a quite static measure, which also highly depends
on the measurement settings, AoR describes the result of an actually moving/flowing powder bed.
However, the AoR turned out not to be a suitable characterisation method for the spray dried powders.
Due to a bad flow behaviour, a larger orifice than the recommended orifice of 10 mm (in DIN ISO
4324) had to be used. Moreover, the powders had to be forced through the orifice. The fact that for
pulmonary hydrophilic powders a large orifice of 25 mm had to be used and in the other cases a
smaller orifice sufficed of 15 mm shows a trend to better flowability for hydrophobic formulations and
powders with larger particle size.
The more dynamic test of flowing through an orifice showed similar problems and likewise a
trend to a decreased flowability of small, wrinkled, hydrophilic powders (P/W/phil). The formulation
had to be forced through the orifice the indentations could interlock. This test also allows for a rough
estimation of powder flow for micronised spray dried powders.
In summary, the result of these flowability tests being proposed by the Ph. Eur. was the
confirm ti of unsuitability of these tests for spray dried formulations for pulmonary and nasal
applications. They are able to show a trend for flow racteristics but cannot m k precis distinct ons.
Therefore, instead of thes tests, which are meant for freely flowable powders, studies with an
FT4 powder rheometer were conducted. It conduc s dyn mic tests with tandardi ed movement.
With this the powder stability, sensitivity to variable flow rates, compr ssibility, basic flow energy, wall
friction angle, and flow function coefficient were determined.
3.2. Results of FT4 Measurements
Prior to conducting the powder rheology measur ments, a stability test was typically carried
out to get an idea of whether the pow ers may change their flow characteristics during testing or
processing. Cohesive powders can undergo agglomeration and change the flow behaviour during
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testing [16]. Therefore, the stability index was determined. The sequence of identical tests allows
detecting changes in powders and the cause for them.
All tested powders exhibited a stability index (SI) above 1 indicating an instable powder bed
(Table 3). The reason for this instability may be de-aeration and formation of larger agglomerates [16].
Due to the escaping air, the particle packing was denser, and consequently, more energy was needed to
stir the powder as the particles were in closer contact with each other. The entrapped air seemed to
escape better due to fewer agglomerates from the bulk in hydrophobic powders, causing an increase in
the energy needed to stir the powder. The interlocking of the indentations in case of wrinkled particles
further hampered the stirring resulting in higher SIs.
Table 3. Characterisation of pulmonary and nasal formulations with FT4 Powder Rheometer. All values
are mean values of a threefold determination ± standard deviation.
Parameter P/S/phil P/W/phil P/S/phob P/W/phob N/S/phil N/W/phil N/S/phob N/W/phob
SI 1.30 ± 0.04 1.35 ± 0.14 2.71 ± 0.24 4.60 ± 0.58 1.31 ± 0.08 1.14 ± 0.11 1.28 ± 0.05 1.37 ± 0.22
BFE in mJ 38.7 ± 3.72 23.6 ± 1.85 14.93 ± 0.21 19.50 ± 2.35 31.6 ± 1.21 54.1 ± 0.65 22.89 ± 0.64 15.55 ± 0.77
FRI 2.46 ± 0.41 3.31 ± 0.71 4.87 ± 0.21 3.82 ± 0.19 2.37 ± 0.06 1.63 ± 0.01 2.21 ± 0.12 2.28 ± 0.14
SE in mJ 4.85 ± 0.67 5.11 ± 1.59 3.51 ± 0.57 3.56 ± 0.19 3.19 ± 0.19 3.23 ± 0.11 1.80 ± 0.03 2.10 ± 0.05
ffc 3.30 ± 0.6 1.99 ± 0.16 5.27 ± 0.46 4.15 ± 0.03 7.4 ± 0.1 8.8 ± 1.4 22.5 ± 3.4 14.7 ± 0.3
Compress
(15 kPa) in % 48 ± 2 41 ± 1 47 ± 6 42 ± 2 22 ± 1 18 ± 0 16 ± 0 33 ± 1
Additionally, compressibility can change flow behaviour leading to caking and an increased
energy needed during stirring and hence, formation of an instable powder. Other factors like moisture
uptake and incurrence of electrostatic charge can as well lead to enhanced agglomeration and raise the
SI. For nasal formulations with a broad particle size distribution, segregation can occur and change the
measured energy as smaller particles are packed more efficiently [16].
The BFE test measures the energy needed to establish a flow pattern producing a high stress flow
mode in the powder in a downward rotation through the powder bed [17]. A relation of the flow
pattern to a given process is not necessarily possible as the powder is confined in the vessel and is
being pushed downward to the vessel floor. Therefore, compressibility is a factor, which may influence
the result [24]. Further, the BFE is dependent on many variables. These factors are particle size, PSD,
cohesiveness, density and moisture content, to mention some [17]. Therefore, nasal formulations with
a larger particle size and mass will require more energy to be stirred than pulmonary formulations
(Table 3). The overall needed energy is very low due to the low density resulting from hollow spheres,
compared to e.g., a finely milled lactose of 20 µm with a BFE ~ 600 mJ [24]. Hydrophobic particles
needed less energy to be stirred, due to less and less stable agglomerates compared to hydrophilic
formulations; meanwhile, a wrinkled morphology can hamper the flow as observed for N/W/phil.
The increased BFE of hydrophilic spherical pulmonary particles compared to the wrinkled particles
was observed, because the agglomerates of P/S/phil required a higher stirring energy compared to the
interlocked wrinkled particles.
The FRI was measured as the processing steps oftentimes include stirring motions at different
speeds. The powder being subjected to this may be sensitive to different flow rates, so gaining an
understanding in that aspect is important. All pulmonary powders except P/S/phil exhibited a high
sensitivity to change in flow rate and required a higher energy to be stirred at lower stirring speed.
This may be caused by less air in the bulk at low flow rates and the material being more consolidated
locally by the blade [18]. This is an often-observed behaviour of cohesive materials. Nasal particles
exhibited an intermediate sensitivity to change in flow rate.
Comparing the compressibility indices of the tapped density as per Ph. Eur. with the
FT4 measurements, the same trend—larger particles are less compressible—was seen but the actual
values differ for some samples, which can be explained by the differences in the measurement procedure.
During the FT4 measurement, the powders are conditioned to ensure the same packing of the particles.
Therefore, the FT4 measurement is more objective and reproducible, whereas the measurement with a
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cylinder as per Ph. Eur. is more dependent on the user and used cylinder. Under maximal pressure of
the vented piston of the FT4 (a piston that allows the air to escape through a steel net), the influence of
the morphology could be observed, as the compressibility of wrinkled particles was lower than for
spherical particles due to their shape independent of the surface. The unusual good compressibility of
N/W/phob could be explained by possible fragmentation of the particles and a resulting reduction
of volume. Particles containing leucine can be thin walled due to the formation process with leucine
precipitating fast at the surface and forming a coherent shell restricting the water vapour to the
core [12]. As the pressure increases, the coherent shell is expanded resulting in thin-walled collapsed
particles [12]. Consequently, the mechanical stability can be reduced. This can be observed in Figure 4.
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Powder rheological tests conducted with the FT4 proved to be more suitable for spray dried
powders. They all showed similar trends in terms of cohesiv ness and flow characteristics.
The flowabilit of the pow ers was best escrib d by the ffc.
3.3. Results of Filling Trials
Filling trials were conducted with a vacuum drum and a dosator system, which both fill
volumetrically. The filling process was evaluated and tried to correlate to one of the flowability tests
described previously with the aim to be able to predict the fillability of powders with a certain filling
system based on a simple flowability test. During the filling trials, it turned out that not all formulations
could be successfully filled with the filling equipment used.
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3.3.1. Drum Filling
The drum system offers the possibility of low dose filling and typically is a filling process with a
low variability. A usual RSD in filling with the vacuum drum is <3% [25]. Filled doses depend on
the size of the dosing bore and the used vacuum. In literature, interactive blends were filled with a
vacuum of –0.4 bars representing mild filling conditions [26]. As flowability is especially impaired for
hydrophilic pulmonary formulations, it was expected that these powders are either not fillable because
of the occurrence of arching in the hopper of the drum, which is a common problem for cohesive
powders [27], or will be filled with high variability.
Results showed, that hydrophilic pulmonary powders were filled with a higher variability (RSD ~
6%) than usually seen for the drum system (Table 4).
Table 4. Fill weights with standard deviation and relative standard deviation (RSD) of n = 20 dosing
procedures for the dosator and drum system. n.a. = not available, if the filling could not be conducted.
P/S/phil P/W/phil P/S/phob P/W/phob N/S/phil N/W/phil N/S/phob N/W/phob
Fill weight in mg
drum system 6.10 ± 0.36 7.78 ± 0.38 11.92 ± 0.08 9.57 ± 0.18 17.37 ± 0.10 18.50 ± 0.17 19.37 ± 0.08 13.49 ± 0.12
RSD in % 5.84 4.85 0.66 1.89 0.58 0.95 0.41 0.91
Fill weight in mg
dosator system 9.89 ± 0.5 9.81 ± 0.66 n.a. n.a. 16.12 ± 0.67 24.36 ± 1.16 20.40 ± 0.81 7.27 ± 1.15
RSD in % 5.03 6.70 n.a. n.a. 4.16 4.77 3.98 15.77
All formulations could be easily filled with the drum except the hydrophilic pulmonary powders.
Here uncontrolled agglomeration, adhesion to walls and arching occurred in the powder container.
Consequently, the variability of these filling trials exhibited an RSD > 3%. The filling of these powders
was repeated, and the success of filling and the variability was found to be dependent on the occurrence
of these phenomena. As the filling trials were conducted under ambient environmental conditions,
factors like humidity are still under investigation. Pulmonary hydrophobic and nasal powders
were filled easily with RSD < 2% without arching or rathole formation. A wrinkled morphology
seemed to interfere with filling trials, as RSD was higher for all wrinkled samples except hydrophilic
pulmonary powders.
The best characterisation methods to predict fillability with the drum system seem to be the ffc
and SE. Powders with low cohesion and therefore good flowability are fillable with the drum system,
whereas an ffc < 4 and SE ~ 5 indicate poor flow behaviour and are not reproducibly fillable with the
drum system, as arching and uncontrolled agglomeration obstruct the filling process. A correlation of
the RSD and the ffc could be found for the pulmonary formulations but not for the nasal formulations,
as they all are fillable (Figure 5).
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3.3.2. osator filling
The dosator syste is an established filling syste for all kinds of po ders. dose is separated
fro the powder bed, compacted, and retained in the pin. Plug formation in the pin is needed to allow
powder transfer to the capsule. The plug formation depends on the compaction and arch formation,
therefore large particles with excellent flow behaviour and the inability to form the needed plugs
cannot be filled with the dosator system [14].
In ter s of spray dried po ders, so e challenges occurred. Filling of hydrophilic for ulations
as successful, hereas hydrophobic for ulations displayed a ore challenging filling behaviour.
Pul onary hydrophobic po ders could be compacted but not retained in the pin and thus could
not be filled. It has been described in the literature that cohesiveness is an important factor in
dosator filling trials [14] and apparently the particle cohesion in those formulations was not intense
enough to keep the powder plug stable. Nasal hydrophilic powders had a better po der flo ability
res lting in ore ense po er beds. At the same time, they showed increased cohesiveness due
to their hydrophilic surface compared to their hydrophobic counterparts, as seen fro higher S
val es, hich allo e the for ation of stable plugs. arger s herical an hy ro hobic articles
( /S/phob) showed excellent flowability in shear cell measurements and had a comparably high bulk
density. Thus, the prepared powder bed in the reservoir was very uniform and dense allowing the
dosator to separate and compact a large powder mass, which appears to be beneficial in this setting.
For asal wri kled particles, the indentations could hamper a nifor owder bed preparation with
density differences i the powder bed and therefore resulted in unsuccessful filling in terms of RSD.
For larger powders, the formation of a uniform and dense powder bed in the reservoir seems to be
key to successful filling. All wrinkled formulations showed a higher RSD that could result from an
inconsistent powder bed, as the particles with indentations could not be aligned as well as spherical
particles. Furthermore, filling trials with the dosator system showed an overall igher variability
than filling trials with the drum system. A possible reason for this could be the general difficulties
in uniform powder bed preparati n. It has to be menti ed t at sticking of p w er as a thin layer
to the outer wall of the pin was noted in some cases. The vibrati n during the critical process steps
(powder ejection), however, was not e ough to shake the powder off and influence the fill weight as
Pharmaceutics 2020, 12, 14 13 of 15
it is a manually operated testing station. In a faster filling process, this might be a problem, which
needs attention.
A correlation of the ffc and SE with filling success was found for pulmonary powders in the way
that small powders with an ffc > 4 and SE < 5 resulted in an unsuccessful filling session. As nasal
powders all exhibited good flow behaviour with an ffc > 4 and could be filled successfully with the
dosator, the particle size seems to have a major influence. The fill weight showed no clear correlation
to bulk or tapped densitym as the extent of compression during the powder bed preparation by
removing excessive powder could not be taken into account. Other correlations, such as particle size
and compressibility as proposed for different powders [14], were not observed. The slightly different
powder bed preparation and filling process compared to literature [14,25] could have caused this.
The main factor for the mass filled into the capsules in the present filling process is the uniformly packed
powder reservoir and powder bed height, which was prepared manually. In literature, the powder bed
is de-aerated ensuring a homogeneous powder packaging. Further, the volume of the dosing chamber
is pre-set through the height of the inner piston in the pin. The pin dives into the powder bed causing
a pre-compression of the powder. Therefore, a correlation can be found in the literature that smaller
particle size and high compression increase the fill weight [14].
Overall, it appeared that the better flowable powders were easy to fill with the vacuum drum
system, whereas the more cohesive powders exhibited some difficulties in filling the bore consistently.
It has to be kept in mind that those filling trials were performed with table-top, single dose versions
of the respective equipment, which was operated at low speed. Simultaneous multiple dosing at
production speed may impose different challenges.
3.4. Aerodynamic Performance
Capsules filled manually with a spatula and capsules filled with the filling systems were assessed
for their aerodynamic performance to evaluate the potential impact of powder change in dosing.
To avoid an influence of differing fill weights between manually filled and machine-filled capsules,
the fill weight of the manually filled capsules was adjusted to the machine-fill weights (i.e., 9 mg
for P/S/phil and 12 mg for P/S/phob). The emitted dose from the inhaler and the fine particle
fraction based on the emitted dose were investigated. It was anticipated that the filling processes
could have an influence on the aerodynamic performance as the consolidation of the powder into a
plug in the filling process could hamper the dispersion of the formed plug from the inhaler device.
Consequently, the emitted dose and/or fine particle fraction could decrease.
As an example, capsules filled with hydrophobic pulmonary formulations were assessed in terms
of emitted dose comparing manual and drum filling (as they were not fillable with the dosator system).
Manually filled capsules of P/S/phob had an emitted dose for the Twister® device of 66 ± 3% (mean
value of five consecutive shots ± standard deviation). Capsules filled with the drum system resulted in
emitted doses of 64 ± 6% for the Twister® device. There is no statistically significant difference in the
emitted doses, but a trend is seen to slightly lower emitted doses for both inhalers if the powder is
filled with the drum.
The fine particle fraction of manually filled capsules of P/S/phob for the Twister® device was
determined to be 72 ± 2%. A statistically significant reduction to 67 ± 1% (p = 0.005) was observed for
capsules filled with the drum system. This can be a result of a hampered dispersion from the device
due to the compression of the powder to a plug.
The hydrophilic pulmonary formulation P/S/phil being filled with the dosator system showed no
statistically significant difference in the emitted dose assessment compared to manually filled capsules.
P/S/phil had an emitted dose for the manually filled capsules of 61 ± 5% and dosator filled capsules of
65 ± 21% (both from the Twister® device). As the mass variability of the dosator-filled capsules was
very high, this also impacted the emitted dose result.
The fine particle fraction for P/S/phil of manually filled capsules and the Twister® device was
found to be higher than for the dosator-filled capsules. A reduction from 39 ± 2% (manually filled
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capsules) to 35 ± 6% (dosator-filled) was observed. Furthermore, the variability increased with the
dosator-filled capsules as the dispersion from the plugs was hampered. Visual inspection of the devices
further revealed that dosator powder plugs were not dispersed completely, but larger fragments
instead of fine deposited material was left in the device. This did not alter the overall deposition profile
nor device retention in the current study but indicates that dispersing forces in the Twister were not
intense enough to fully disperse the plugs.
Overall, it can be concluded that the filling process may have an influence on the aerodynamic
performance, so careful investigation is needed.
4. Conclusion
In this work, spray dried powders for pulmonary and nasal application with their respective
particle size were produced, characterized, and filled with the drum and dosator system. It could
be shown that the classic flowability characterisation according to the Ph. Eur. is not suitable
for the powders as results were not discriminative nor predictive for powder behaviour in filling.
Powder rheometer measurements can discriminate better in terms of flow behaviour, especially the ffc
and SE. These values can also be applied to predict the success of filling trials for the drum system.
Other factors like BFE and compressibility showed no correlation to the filling trials but may be helpful
parameters to gain deeper insight into powder characteristics. Filling processes can also have an
impact on the aerodynamic performance, which should be taken into account.
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